US-based biotechnology company Tango Therapeutics has dosed the first patient in its Phase I/II trial of TNG260 in combination with pembrolizumab.
The trial will evaluate the combination therapy’s efficacy in treating locally advanced or metastatic solid tumours with STK11 loss-of-function mutations.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
STK11 loss-of-function mutations are seen in various types of cancer, including breast, cervical, pancreatic and non-small cell lung cancers, as well as carcinomas of unknown primary.
The study intends to assess TNG260’s pharmacodynamics, pharmacokinetics, efficacy and safety both alone and in combination with pembrolizumab in patients with STK11-mutant cancers.
Tango Therapeutics research and development president Adam Crystal said: “The TNG260 Phase I/II clinical trial is the first trial to use genetic patient selection in combination with checkpoint inhibitor therapy, to reverse the cancer-specific immune evasion caused by STK11 loss of function mutations.
“Resistance to immunotherapy is a major challenge faced by patients with STK11-mutant cancers, which TNG260 is specifically designed to overcome.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Our pipeline of precision oncology treatments based on synthetic lethality has advanced significantly this year, as we now have initiated three clinical trials.”
TNG260 inhibits the Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) complex.
During previous pre-clinical studies, the drug caused complete remission and the production of immune memory cells that help in preventing re-implantation and regrowth of the tumour.
Earlier this month, Tango Therapeutics dosed the first patient in its Phase I/II trial of TNG462 evaluating patients with methylthioadenosine phosphorylase (MTAP) deleted solid tumours.
The study was designed to assess TNG462 efficacy, safety, pharmacokinetics and pharmacodynamics in MTAP-deleted solid tumours, including non-small cell lung cancer, mesothelioma and cholangiocarcinoma.
In April 2023, the US Food and Drug Administration (FDA) granted fast-track designation to TNG260 in combination with an anti-PD-1 antibody for treating patients with previously treated advanced non-small cell lung cancer with STK11-mutations.
